“HRT amniotic biologics are demonstrating to be an ideal solution for the treatment of many wounds and surgical challenges,” commented Henry McLeod, VP “We have developed one of the industries most diverse active amniotic biologic lin
REDONDO BEACH, CA (PRWEB) September 18, 2014
Human Regenerative Technologies LLC (HRT™) is a regenerative solutions biotechnology company engaged in the development and commercialization of novel human-based active Extracellular Matrix (ECM) biologic products derived from human amniotic and placental tissues. HRT's first generation of commercially available biologics successfully combines science and technology in the procurement, processing and delivery of innovative amniotic tissues and forms.
HRT will be showcasing its surgical amniotic product line of AmnioPro-C Flowable, AmnioPro – A Flowable, AmnioPro45™ Membrane, AmnioPro200™ Membrane and its In-Office amniotic product line to surgeons and prospective partner companies at the 2014 Annual American Orthopedic Foot and Ankle Society Meeting (AOFAS) September 21st-23rd in Chicago.
HRT continues to expand its national and international distribution network and private label opportunities with synergistic medical companies.
“HRT is very excited to be sharing clinical application information on AmnioPro45™ Membrane, AmnioPro200™ Membrane, AmnioPro-A™, and AmnioPro-C™, part of a complete portfolio of advanced biologics for Wounds, Foot & Ankle, Urology, Podiatry, OBGYN, ENT, Dental, Oral and Maxillofacial, Orthopedics, Spine, and Plastics applications with surgeons and prospective partners.”
“HRT amniotic biologics are demonstrating to be an ideal solution for the treatment of many wounds and surgical challenges,” commented Henry McLeod, VP Corporate Development “We have developed one of the industries most diverse active amniotic biologic lines utilizing our proprietary HydraTek™ process, and are thrilled to be sharing them with the Foot & Ankle community. Our mission continues to be advancing our novel line of placental tissue-based products with the goal of enhancing the quality of patient care in a broad range of clinical applications.”
About Human Regenerative Technologies LLC (HRT) Harnessing the Regenerative Power of the Body™,:
Human Regenerative Technologies, LLC (HRT™) is focused on advancing the understanding of the science and clinical application of human derived protein and cellular therapies to assist in providing biologic solutions for wound care, urology, gynecology, general, orthopedics, sports medicine and plastic surgery procedures.
HRT's first generation of commercially available biologics successfully combines science and technology in the procurement, processing and delivery of innovative amniotic tissues and forms.
These next generation amniotic wound coverings have been specifically engineered for improved handling, delivery and performance characteristics. HRT also developed the proprietary Hydratek™ Process, a bio-aware controlled-rate process, to better preserve the structural integrity and biomechanical properties of these viable tissues. The result is a comprehensive line of biologics that is simpler to handle, easier to apply, and designed to address the many challenges that surgeons face in a wide range of surgical defects.
For more information, visit our website at http://www.humantissue.com or email: info(at)humantissue(dot)com